| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-12-19 | AUY922 | non small cell lung cancer | 2 | Novartis (Switzerland) Vernalis (UK) | Cancer - Oncology |
| 2014-12-19 | IPH2201 (anti-NKG2A antibody) | squamous cell carcinoma of the oral cavity |
2 | Innate Pharma (France) | Cancer - Oncology |
| 2014-12-19 | Kadcyla® (trastuzumab emtansine) plus Perjeta® (pertuzumab), Kadcyla alone, and Herceptin® (trastuzumab) plus taxane chemotherapy | previously untreated advanced HER2-positive breast cancer |
3 | Roche (Switzerland) | Cancer - Oncology |
| 2014-12-19 | Micropump® technology applied to sodium oxybate | narcolepsy |
1 | Flamel Technologies (France) | Neurological diseases |
| 2014-12-18 | masitinib in combination with three standard-of-care chemotherapies including FOLFIRI, FOLFOX, and gemcitabine | nonresectable, metastatic colorectal cancer after progression to first-line treatment | 2 | AB Science (France) | Cancer - Oncology |
| 2014-12-18 | SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin | acute myeloid leukemia |
1b | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-12-18 | pregabalin controlled-release (CR) formulation | postherpetic neuralgia |
3 | Pfizer (USA - NY) | CNS diseases - Neurological diseases |
| 2014-12-17 | LR769 - recombinant form of human Factor VIIa | congenital hemophilia A or B with inhibitors |
3 | LFB (France) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2014-12-17 | NuQ® diagnostic platform | lung cancer |
VolitionRX (Singapore) University Hospital Bonn (Germany) | Cancer - Oncology - Diagnostic | |
| 2014-12-17 | desmoteplase | acute ischaemic stroke | 3 | Lundbeck (Denmark) | Cerebrovascular diseases |
| 2014-12-15 | palbociclib | estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer |
2 | Pfizer (USA - NY) | Cancer - Oncology |
| 2014-12-12 | BL-8040 | hypoplastic myelodysplastic syndrome (hMDS) aplastic anemia (AA) |
1-2 | BioLineRx (Israel) | Cancer - Oncology |
| 2014-12-12 | BL-8040 | acute myeloid leukemia with FLT3 mutations |
1-2 | BioLineRx (Israel) | Cancer - Oncology |
| 2014-12-11 | VR475 | asthma |
2b-3 | Vectura (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2014-12-11 | brexpiprazole (OPC-34712) | schizophrenia |
3 | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | Mental diseases |
| 2014-12-11 | Brintellix® (vortioxetine) | major depressive disorder |
Lundbeck (Denmark) | CNS diseases - Mental diseases | |
| 2014-12-11 | duvelisib (IPI-145) | relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) | 1 | Infinity Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2014-12-11 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | diffuse large B-cell lymphoma (DLBCL) | 2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-12-11 | AGT-182 | mucopolysaccharidosis II (MPS II, Hunter Syndrome) | 1-2 | Armagen (USA - CA) | Rare diseases - Genetic diseases |
| 2014-12-10 | H1/IC31® (H1IC vaccine candidate from SSI is a recombinant subunit vaccine based on two important TB antigens resulting from SSI’s research pipeline combined with Intercell’s proprietary adjuvant IC31® and ultimately targeted against adults and adolescents.) | tuberculosis |
2 | Intercell (Austria), now Valneva - Statens Serum Institut (Denmark) | Infectious diseases |
